Harvard Bioscience lifts full-year outlook as Q2 revenue climbs 11%
HBIO sits 71% above its 52-week low of $3.755 on elevated volume (1.9× avg).
Summary
Harvard Bioscience reported Q2 2026 revenue of $22.7 million, up 11% year-over-year, and raised its full-year revenue growth guidance to 3%-5%. Adjusted EBITDA improved to $1.7 million.
Key Events · Earnings and Guidance · HBIO
-
Q2 Revenue Beats with 11% Growth
Revenue reached $22.7 million, up from $20.5 million in Q2 2025, driven by strong demand in telemetry and CMT products.
-
Full-Year Revenue Guidance Raised
Management now expects 3%-5% revenue growth for 2026, up from prior implied guidance, reflecting confidence in commercial traction.
-
Adjusted EBITDA Improves
Adjusted EBITDA rose to $1.7 million from $1.5 million a year ago, with adjusted EBITDA margin steady at 7.3%.
-
Q3 Guidance Issued
Q3 revenue is expected between $21.0 million and $22.6 million, with adjusted EBITDA of $1.5 million to $2.5 million.
Analysis · HBIO · Industrial Applications And Services
A strong second quarter saw Harvard Bioscience post 11% revenue growth to $22.7 million, fueled by demand for its telemetry and cellular/molecular technology products. The company raised its full-year 2026 revenue guidance to 3%-5% growth, underscoring confidence in its commercial momentum. Adjusted EBITDA improved to $1.7 million from $1.5 million a year ago, though net losses widened slightly. For a micro-cap that recently emerged from going-concern doubts, the raised outlook and solid top-line beat make this a notably positive update.
At the time of this filing, HBIO was trading at $6.41 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $28.8M. The 52-week trading range was $3.76 to $9.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.